TissueTech fleshes out $10M equity round

Thu, 08/22/2013 - 10:32am
Mass Device

TissueTech says it's raised $10 million in equity financing for its regenerative medicine technology.

TissueTech fleshes out $10M equity round

TissueTech Inc. said it pulled down $10 million from a pair of venture capital shops to back its regenerative medicine subsidiaries, Bio-Tissue and Amniox Medical.

The equity round came from Ballast Point Ventures and River Cities Capital Funds, according to a press release.

Doral, Fla.-based TissueTech makes amniotic membrane- and umbilical cord-based products designed to treat ocular surface diseases (Bio-Tissue) and musculoskeletal conditions and wound care (Amniox Medical), according to the release.

The cash is earmarked for commercialization and R&D, TissueTech said.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.